<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03139240</url>
  </required_header>
  <id_info>
    <org_study_id>16845</org_study_id>
    <nct_id>NCT03139240</nct_id>
  </id_info>
  <brief_title>Opioid Analgesia for MAB</brief_title>
  <official_title>Opioid Analgesia for MAB: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Family Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our primary objective will be to determine if a strong opioid, oxycodone, given at a dose
      recommended for severe pain in addition to ibuprofen decreases maximum pain scores compared
      to ibuprofen and placebo in women undergoing medical abortion (MAB). Results of this study
      will help future providers understand whether prescribing opioids are an important adjunct
      for pain control in women undergoing MAB.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will include 152 women undergoing MAB. Women will be randomized to oxycodone 10mg
      oral versus placebo and stratified by gestational age (&lt;7wks, 7-10wks). The primary outcome
      will be maximum reported pain score measured at 6-8 hours and 24 hours after misoprostol
      administration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Actual">May 31, 2018</completion_date>
  <primary_completion_date type="Actual">May 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Maximum Self-reported Pain Score</measure>
    <time_frame>24 hours after misoprostol administration</time_frame>
    <description>Women text responses through two surveys within 24 hours after misoprostol administration indicating their maximum self-reported pain score on an 11-point Numeric Pain Rating Scale (0 = no pain, 5 = moderate pain, and 10 = worst possible pain).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>&lt;7 Weeks of Gestation - Maximum Self-reported Pain Score</measure>
    <time_frame>24 hours after misoprostol administration</time_frame>
    <description>Women text responses through two surveys within 24 hours after misoprostol administration indicating their maximum self-reported pain score on an 11-point Numeric Pain Rating Scale (0 = no pain, 5 = moderate pain, and 10 = worst possible pain).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>7-10 Weeks Gestation - Maximum Self-reported Pain Score</measure>
    <time_frame>24 hours after misoprostol administration</time_frame>
    <description>Women text responses through two surveys within 24 hours after misoprostol administration indicating their maximum self-reported pain score on an 11-point Numeric Pain Rating Scale (0 = no pain, 5 = moderate pain, and 10 = worst possible pain).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">172</enrollment>
  <condition>MAB</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Gestational age &lt;7 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women with a gestational age &lt;7 weeks will be randomized to oxycodone 10mg oral vs placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gestational age 7-10w0d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women with a gestational age 7-10w0d will be randomized to oxycodone 10mg oral vs placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone 10mg oral</intervention_name>
    <description>Oxycodone 10mg oral given for pain control in addition to standard of care medications in women undergoing medical abortion</description>
    <arm_group_label>Gestational age 7-10w0d</arm_group_label>
    <arm_group_label>Gestational age &lt;7 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo given in addition to standard of care medications in women undergoing medical abortion</description>
    <arm_group_label>Gestational age 7-10w0d</arm_group_label>
    <arm_group_label>Gestational age &lt;7 weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 years or older

          -  Seeking elective medical abortion

          -  In good health

          -  Pregnancy with intrauterine gestational sac up to 10 0/7 weeks, dated by ultrasound

          -  Able and willing to receive text messages via phone

          -  Literate in English

          -  Able and willing to give informed consent and agree to the study terms

          -  Have assistance at home; no motor vehicle use while taking study medications

        Exclusion Criteria:

          -  Lack of access to cell phone and texting capabilities

          -  Early pregnancy failure

          -  Contraindications to the study medications: Oxycodone, Ibuprofen

          -  Contraindications to medical abortion with Mifepristone or Misoprostol

          -  History of methadone or heroin use

          -  Used alcohol in the past 24 hours

          -  Used marijuana &gt;4 times per week

          -  Any opioid in the past 30 days

          -  Using additional pain medications
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site 1</name>
      <address>
        <city>Beaverton</city>
        <state>Oregon</state>
        <zip>97005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 28, 2017</study_first_submitted>
  <study_first_submitted_qc>May 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2017</study_first_posted>
  <results_first_submitted>June 6, 2019</results_first_submitted>
  <results_first_submitted_qc>July 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 13, 2019</results_first_posted>
  <last_update_submitted>August 18, 2019</last_update_submitted>
  <last_update_submitted_qc>August 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Alyssa Colwill</investigator_full_name>
    <investigator_title>MD, Instructor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT03139240/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Oxycodone: &lt;7 Weeks of Gestation</title>
          <description>Oxycodone 10mg oral: Oxycodone 10mg oral given for pain control in addition to standard of care medications in women undergoing medical abortion
Women with a gestational age &lt;7 weeks randomized to oxycodone 10mg oral</description>
        </group>
        <group group_id="P2">
          <title>Placebo: &lt;7 Weeks Gestational Age</title>
          <description>Placebo: Placebo given in addition to standard of care medications in women undergoing medical abortion
Women with a gestational age &lt;7 weeks and women with a gestational age 7-10w0d randomized to placebo</description>
        </group>
        <group group_id="P3">
          <title>Oxycodone: 7-10w0d Gestational Age</title>
          <description>Oxycodone 10mg oral: Oxycodone 10mg oral given for pain control in addition to standard of care medications in women undergoing medical abortion
Women with a gestational age 7-10w0d randomized to oxycodone 10mg oral</description>
        </group>
        <group group_id="P4">
          <title>Placebo: 7-10w0d Gestational Age</title>
          <description>Placebo: Placebo given in addition to standard of care medications in women undergoing medical abortion
Women with a gestational age &lt;7 weeks and women with a gestational age 7-10w0d randomized to placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oxycodone: &lt;7 Weeks Gestational Age</title>
          <description>Oxycodone 10mg oral: Oxycodone 10mg oral given for pain control in addition to standard of care medications in women undergoing medical abortion
Women with a gestational age &lt;7 weeks randomized to oxycodone 10mg oral</description>
        </group>
        <group group_id="B2">
          <title>Placebo: &lt;7 Weeks Gestational Age</title>
          <description>Placebo: Placebo given in addition to standard of care medications in women undergoing medical abortion
Women with a gestational age &lt;7 weeks randomized to placebo</description>
        </group>
        <group group_id="B3">
          <title>Oxycodone: 7-10w0d Weeks Gestational Age</title>
          <description>Oxycodone 10mg oral: Oxycodone 10mg oral given for pain control in addition to standard of care medications in women undergoing medical abortion
Women with a gestational age 7-10w0d randomized to oxycodone 10mg oral</description>
        </group>
        <group group_id="B4">
          <title>Placebo: 7-10w0d Weeks Gestational Age</title>
          <description>Placebo: Placebo given in addition to standard of care medications in women undergoing medical abortion
Women with a gestational age 7-10w0d randomized to placebo</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
            <count group_id="B2" value="48"/>
            <count group_id="B3" value="38"/>
            <count group_id="B4" value="38"/>
            <count group_id="B5" value="172"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="172"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="172"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White/Non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Maximum Self-reported Pain Score</title>
        <description>Women text responses through two surveys within 24 hours after misoprostol administration indicating their maximum self-reported pain score on an 11-point Numeric Pain Rating Scale (0 = no pain, 5 = moderate pain, and 10 = worst possible pain).</description>
        <time_frame>24 hours after misoprostol administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxycodone Arm</title>
            <description>Oxycodone 10mg oral: Oxycodone 10mg oral given for pain control in addition to standard of care medications in women undergoing medical abortion
Women with a gestational age &lt;7 weeks and women with a gestational age 7-10w0d randomized to oxycodone 10mg oral</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Placebo: Placebo given in addition to standard of care medications in women undergoing medical abortion
Women with a gestational age &lt;7 weeks and women with a gestational age 7-10w0d randomized to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Maximum Self-reported Pain Score</title>
          <description>Women text responses through two surveys within 24 hours after misoprostol administration indicating their maximum self-reported pain score on an 11-point Numeric Pain Rating Scale (0 = no pain, 5 = moderate pain, and 10 = worst possible pain).</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="2" upper_limit="10"/>
                    <measurement group_id="O2" value="8" lower_limit="1" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>&lt;7 Weeks of Gestation - Maximum Self-reported Pain Score</title>
        <description>Women text responses through two surveys within 24 hours after misoprostol administration indicating their maximum self-reported pain score on an 11-point Numeric Pain Rating Scale (0 = no pain, 5 = moderate pain, and 10 = worst possible pain).</description>
        <time_frame>24 hours after misoprostol administration</time_frame>
        <population>Participants at &lt;7 weeks of Gestation were assessed. Participants who were &quot;lost to follow-up&quot; were excluded from this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxycodone</title>
            <description>Oxycodone 10mg oral: Oxycodone 10mg oral given for pain control in addition to standard of care medications in women undergoing medical abortion
Women with a gestational age &lt;7 weeks randomized to oxycodone 10mg oral</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo given in addition to standard of care medications in women undergoing medical abortion
Women with a gestational age &lt;7 weeks randomized to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>&lt;7 Weeks of Gestation - Maximum Self-reported Pain Score</title>
          <description>Women text responses through two surveys within 24 hours after misoprostol administration indicating their maximum self-reported pain score on an 11-point Numeric Pain Rating Scale (0 = no pain, 5 = moderate pain, and 10 = worst possible pain).</description>
          <population>Participants at &lt;7 weeks of Gestation were assessed. Participants who were &quot;lost to follow-up&quot; were excluded from this analysis.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="2" upper_limit="10"/>
                    <measurement group_id="O2" value="8" lower_limit="1" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>7-10 Weeks Gestation - Maximum Self-reported Pain Score</title>
        <description>Women text responses through two surveys within 24 hours after misoprostol administration indicating their maximum self-reported pain score on an 11-point Numeric Pain Rating Scale (0 = no pain, 5 = moderate pain, and 10 = worst possible pain).</description>
        <time_frame>24 hours after misoprostol administration</time_frame>
        <population>Participants at 7-10w0d of Gestation were assessed. Participants who were &quot;lost to follow-up&quot; were excluded from this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxycodone</title>
            <description>Oxycodone 10mg oral: Oxycodone 10mg oral given for pain control in addition to standard of care medications in women undergoing medical abortion
Women with a gestational age &lt;7 weeks randomized to oxycodone 10mg oral</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo given in addition to standard of care medications in women undergoing medical abortion
Women with a gestational age &lt;7 weeks randomized to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>7-10 Weeks Gestation - Maximum Self-reported Pain Score</title>
          <description>Women text responses through two surveys within 24 hours after misoprostol administration indicating their maximum self-reported pain score on an 11-point Numeric Pain Rating Scale (0 = no pain, 5 = moderate pain, and 10 = worst possible pain).</description>
          <population>Participants at 7-10w0d of Gestation were assessed. Participants who were &quot;lost to follow-up&quot; were excluded from this analysis.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="2" upper_limit="10"/>
                    <measurement group_id="O2" value="8" lower_limit="4" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>21 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Oxycodone</title>
          <description>Oxycodone 10mg oral: Oxycodone 10mg oral given for pain control in addition to standard of care medications in women undergoing medical abortion
Women with a gestational age &lt;7 weeks and women with a gestational age 7-10w0d randomized to oxycodone 10mg oral</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: Placebo given in addition to standard of care medications in women undergoing medical abortion
Women with a gestational age &lt;7 weeks and women with a gestational age 7-10w0d randomized to placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ongoing pregnancy</sub_title>
                <description>Resolved with standard treatment measures.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ob/Gyn Regulatory Specialist</name_or_title>
      <organization>Oregon Health &amp; Science University</organization>
      <phone>5034940757</phone>
      <email>mccrimmo@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

